China Approves Trastuzumab Deruxtecan (ENHERTU) Followed by THP for Neoadjuvant HER2-Positive Breast Cancer Based on DESTINY-Breast11
Mar 29, 2026
View online
China Approves Trastuzumab Deruxtecan (ENHERTU) Followed by THP for Neoadjuvant HER2-Positive Breast Cancer Based on DESTINY-Breast11
20 Posts Not To Miss From EBCC 2026
NCCN Annual Conference 2026: The Evolving Treatment Landscape for Gastric, Esophageal, and EGJ Cancers
Vivek Subbiah: ARROW Study Final Results in RET-Positive Lung Cancer
Zimbabwean Nurses Go on Strike to Demand Better Pay
Audrey Hepburn Rare Cancer: Hollywood Legend’s Diagnosis, Final Months and Legacy
Amgen Acquires Oxford Spinout Dark Blue Therapeutics in Up to $840M Deal to Advance AML Treatment
AACR Non-Small Cell Lung Cancer Research Fellowship
Breast Cancer Research Foundation-AACR NextGen Grant for Transformative Cancer Research in Honor of Nancy E. Davidson, MD
2026 Highlights of ASH in Asia-Pacific
APPOS Tampa 2026: Advanced Practice Providers Oncology Summit
The Voice of Oncology
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
